A temperature excursion in a pharma cold chain doesn’t just spoil product. It delays patient treatment and triggers FDA regulatory investigations. Qeep books temperature-controlled carriers with calibrated recorders at 2–8°C or frozen, and reports any excursion in writing when it happens.
Pharmaceutical and healthcare freight operates in a regulatory framework with no tolerance for deviation. Good Distribution Practice (GDP) — under FDA 21 CFR and Health Canada Guidelines — requires documented temperature mapping, validated equipment qualification, and unbroken chain-of-custody from manufacturer to patient. A single temperature excursion can trigger product quarantine, FDA field alert reports, and costly batch investigations. Clinical trial materials add further complexity: IMP (Investigational Medicinal Products) require serialized chain-of-custody, blinded labeling protocols, and site-specific delivery windows that align with investigator schedules. Medical devices add FDA QSR (21 CFR Part 820) and Health Canada MDR compliance requirements. Generalist carriers cannot maintain these standards — healthcare shippers need a partner whose standard operating procedures mirror their own quality systems.
From room-temperature oral solids to liquid-nitrogen cryogenics, Qeep books carriers and partners equipped for each profile across the pharmaceutical cold-chain spectrum, and asks for the equipment documents at every tier.
Biologic drugs, vaccines, and specialty pharma products can be destroyed by a two-hour temperature excursion — sometimes worth millions of dollars per batch. Pre-cooling, continuous data-logger monitoring, alarm response protocols, and qualified thermal packaging are non-negotiable for every movement, including the last-mile leg.
Schedule II-V controlled substances require carrier DEA registration (US) or Health Canada Narcotic and Controlled Substances licensing, facility security protocols, two-person verification at delivery, and destruction manifests for returns. A break in the controlled substance chain-of-custody is a DEA reportable event with potential license revocation consequences.
Investigational products must arrive at clinical sites in the correct kit configuration, under blinded conditions, with the correct temperature record, on a date that aligns with patient dosing visits. Late or incorrect deliveries can invalidate data points in a trial, triggering protocol deviations and increasing development timelines by months.
Pharma shipments increasingly move via a combination of road, air, and last-mile courier — each segment managed by a different operator with different equipment qualification levels. Maintaining a validated, documented chain of temperature across handoffs between carriers requires tightly managed SOPs and real-time data-logger retrieval at each handoff point.
Sterile single-use medical devices can be compromised by moisture ingress, package drop damage, or extreme temperature exposure — rendering them unusable and triggering FDA reportable events. Orthopedic implant sets, surgical instruments, and diagnostic equipment each require specific handling protocols that must be documented in the carrier’s quality management system.
We book temperature-controlled carriers across North America at 2–8°C (refrigerated), -20°C (frozen), and ambient-controlled profiles, and ask for the equipment documents a pharma shipper needs: calibrated data-logger certificates, pre-cool verification records and, where your quality team requires it, trailer qualification. Temperature records are sent to you after delivery.
For controlled substances we book carriers that hold their own DEA registration (US) or Health Canada licence (Canada), with GPS-tracked vehicles and cargo alarm systems, two-person delivery teams for Schedule II shipments, and chain-of-custody documentation that satisfies 21 CFR Part 1301 and NAPRA requirements. We also coordinate destruction manifests for pharmaceutical returns.
Our team arranges IMP shipments from sponsor manufacturing sites to investigator sites under blinded conditions. We coordinate with site coordinators on delivery windows tied to patient visit calendars, keep blinded temperature records with each shipment, and arrange the reverse logistics of unused IMP returns under protocol-specific destruction SOPs.
Sterile medical device shipments are booked on humidity-controlled equipment with drop-height monitoring where required. When storage is needed we use partner warehouses, and book GMP-compliant space through partners when the product calls for it. We coordinate OR delivery scheduling with hospital materials management teams.
When a temperature excursion occurs, we notify the shipper’s QP (Qualified Person) as soon as we know, pull the data-logger record from the carrier, and put the facts in writing: duration, magnitude and what was done about it. Deviation records stay on the load file to support your own CAPA and FDA inspection readiness.
GDP. DEA. FSMA. ICH Q10. No teaching a generalist what pharma freight must clear. We already know.
An excursion is a period where the shipment went outside its specified range. It is not automatically a loss, and treating it as one is as unhelpful as ignoring it. What matters is that it was detected, recorded with the duration and the magnitude, reported promptly, and assessed against the product stability data by somebody qualified to make that call. Many products tolerate a short deviation; some tolerate none. Only the person who owns the product specification can decide, and they can only decide if they are told.
The failure that ruins a healthcare programme is silence. A driver who notices a reading, adjusts the setpoint and says nothing produces a shipment that arrives looking clean with an undocumented gap in its history. From a quality perspective that is worse than a reported excursion, because the whole consignment is now suspect and nobody can bound the exposure. Our standing rule is that the deviation is reported when it happens, in writing, with what was done about it.
Prevention is mostly about the dock rather than the road. A refrigerated trailer maintains temperature, it does not create it, so product loads at its target temperature with the pulp temperature recorded at that point. Door-open time on a warm loading bay costs more than most shippers expect. And the monitoring device has to be calibrated, placed where it reflects the load rather than the airflow, and downloaded at delivery rather than left in a portal that expires before the claim window closes.
Healthcare freight is unusual in that the hard part is often the last two hours rather than the two days before them. Hospital loading docks operate limited receiving hours, frequently with a single dock shared across every department. Clinics and pharmacies may have no dock at all, which means a liftgate and an inside delivery. Distribution centres run booked appointments and will not take a truck that arrives outside its slot. None of this is negotiable on the day.
That means the schedule has to be built backwards from the receiving window with real slack in it, not forwards from the pickup with optimism. A shipment that arrives after receiving closes sits somewhere overnight, and a temperature-controlled consignment sitting in a yard overnight is a conversation nobody wants to have with a quality team. Where the delivery window is narrow and the transit is long, the honest answer is often to depart a day earlier rather than to promise a tighter transit.
Chain of custody through that final step deserves the same discipline as the transit. Who signed, at what time, and against what document. A named signature with a legible time and a piece count is the record that resolves a discrepancy; an illegible scrawl on a driver device is not. Where the consignee requires a specific handover procedure, or a two-person receipt, or a returned copy of a delivery document, that belongs in the booking instructions rather than being discovered at the door.
Health products crossing into Canada answer to more than customs. Drugs, medical devices, natural health products and certain biologics each have their own regulatory regime under Health Canada, with licensing, establishment registration and import requirements that vary by product class. Customs will not release a shipment that another department has not cleared, and discovering that at the border is expensive. The commodity is checked against those requirements before it ships rather than after it is held.
Southbound, the FDA regulates drugs, devices and biologics entering the United States, with its own registration, listing and entry review requirements, and shipments are frequently subject to a review that customs alone would not trigger. As with the northbound direction, this sits alongside the customs entry rather than inside it. The practical consequence is that a healthcare shipment needs its regulatory paperwork assembled with the same lead time as its commercial paperwork, not later.
On the customs mechanics themselves nothing is special: a PARS or PAPS barcode issued by the carrier, the entry filed against it before the truck arrives, and the eManifest transmitted inside the advance window, with the Canadian importer registered on the CARM portal and financial security posted if goods are to be released before payment. What is different is the cost of a hold. A pallet of industrial parts waiting at a border is an inconvenience; a temperature-controlled consignment waiting at a border is a stability clock running down.
Recall response is the part of healthcare freight that decides how a manufacturer is judged when something goes wrong, and it is almost always planned worse than the outbound movement that put the product in the field in the first place. A recall happens on short notice, at a scale the operations team did not forecast, and against a regulatory clock that is watching the total time between the decision and the withdrawal of the affected product. The freight capability behind that response either exists in advance or the recall runs slower than it should.
The design work belongs before the event. Knowing which carriers can be tasked immediately, which have the storage and handling capability to receive returned product, where the quarantine locations are, how the paperwork will be issued and reconciled and who has authority to commit spend during a response, all have to be settled during a quiet period. When those decisions are made during the recall, hours are lost and the decisions are usually worse than the pre-agreed answers would have been.
Reverse product needs its own controls because it is now potentially compromised. Recalled goods should never mix with saleable inventory in a trailer or a warehouse, and the chain of custody from the point of collection to the disposition point has to be provable at the unit or lot level. Sealed handovers, dedicated equipment where volume justifies it and a clean audit record are what make the collection defensible to a regulator later.
Reporting during a recall is a real workload in itself. The regulator wants to see quantities collected, timeframes and outstanding units, and the manufacturer wants the same view for its own management, and neither is served by reports assembled from spreadsheets after the fact. The reporting works best when it is built into the collection process, with figures updated as trucks are unloaded and quarantines are confirmed, so the report at any hour reflects the actual state of the recall rather than the state as of yesterday.
Finally, closure matters as much as the initial response. A recall is not finished when the last truck is unloaded, it is finished when disposition is documented, quantities are reconciled and the regulator has a clean file. Following through on that last mile of the paperwork is where healthcare freight partners either earn or lose the operator’s confidence for the next event, and there is always a next event.
Tell us the origin, destination and mode. A Qeep specialist replies within the hour with live capacity, lane price, and a transit window you can actually plan around.
